Claim your bonus gift: give any amount to get 4 KaiPA coasters! Donate today

Superbugs create super opportunity

Helen Palmer Jun 7, 2007

TEXT OF STORY

MARK AUSTIN THOMAS: Sometimes a hospital isn’t the best place to get well. It’s becoming increasingly full of dangerous bugs resistant to antibiotics. About 5 out of every 100 patients catches an infection there. But, Helen Palmer reports from the Health Desk at WGBH, those statistics represent an opportunity for the pharmaceutical industry.

Helen Palmer: In recent years, terms like Methicillin-resistant Staphylococcusaureus — or MRSA— have begun to trip off our tongues as these dangerous bacteria have become a widespread problem in hospitals. New analysis says the costs are huge.

Mansi Shah: There’s probably about $1.5 billion spent on hospital acquired infections.

Mansi Shah is an analyst with research company Datamonitor. She says the drug industry’s risen to the challenge with effective new but pricey antibacterials. Pfizer’s Zyvox, for example, costs about $150 a day.

Shah: There’s lots of companies who’ve targeted that particular market and there’s lots of drugs in the pipeline targeted towards the MRSA market.

But Shah says choices are very limited for other resistant bacteria, including bugs that cause hospital-acquired pneumonia. Only one company, Johnson & Johnson, has drugs in the pipeline to tackle that. It filed for FDA approval of one just yesterday.

In Boston, I’m Helen Palmer for Marketplace.

TEXT OF STORY

MARK AUSTIN THOMAS: Sometimes a hospital isn’t the best place to get well. It’s becoming increasingly full of dangerous bugs resistant to antibiotics. About 5 out of every 100 patients catches an infection there. But, Helen Palmer reports from the Health Desk at WGBH, those statistics represent an opportunity for the pharmaceutical industry.

Helen Palmer: In recent years, terms like Methicillin-resistant Staphylococcusaureus — or MRSA— have begun to trip off our tongues as these dangerous bacteria have become a widespread problem in hospitals. New analysis says the costs are huge.

Mansi Shah: There’s probably about $1.5 billion spent on hospital acquired infections.

Mansi Shah is an analyst with research company Datamonitor. She says the drug industry’s risen to the challenge with effective new but pricey antibacterials. Pfizer’s Zyvox, for example, costs about $150 a day.

Shah: There’s lots of companies who’ve targeted that particular market and there’s lots of drugs in the pipeline targeted towards the MRSA market.

But Shah says choices are very limited for other resistant bacteria, including bugs that cause hospital-acquired pneumonia. Only one company, Johnson & Johnson, has drugs in the pipeline to tackle that. It filed for FDA approval of one just yesterday.

In Boston, I’m Helen Palmer for Marketplace.

As a nonprofit news organization, our future depends on listeners like you who believe in the power of public service journalism.

Your investment in Marketplace helps us remain paywall-free and ensures everyone has access to trustworthy, unbiased news and information, regardless of their ability to pay.

Donate today — in any amount — to become a Marketplace Investor. Now more than ever, your commitment makes a difference.